Preclinical Cardioembolic Stroke Research Services
A cardioembolic stroke occurs when unwanted materials, such as blood clots, are pumped from the heart into the cerebral circulation. This causes a blood vessel in the brain to become blocked, resulting in damage to brain tissue. Cardioembolism accounts for about 20% of all ischemic strokes. These types of strokes are associated with more severe neurological deficits and poorer outcomes than other stroke categories. Atrial fibrillation is the most common cause of cardioembolic stroke and anticoagulation is usually recommended. However, less than half of patients with atrial fibrillation are prescribed continuous oral anticoagulation because of the risk of bleeding. There is a need to develop safer and easier-to-use antithrombotic drugs and definitive treatment of atrial fibrillation.
Fig. 1 Heart diseases associated with stroke. (Kato, et al., 2024)
High-quality preclinical research and drug development are essential for addressing the challenges posed by cardioembolic stroke. At Ace Therapeutics, we are dedicated to providing valuable insights into this complex disease. By tailoring our studies to meet your specific preclinical research needs in cardioembolic stroke, we deliver comprehensive data on the potential of your drug candidates.
Types of Biomarkers We Can Develop for Cardioembolic Stroke
Our team of experts specializes in the comprehensive identification and validation of candidate biomarkers of atrial cardiopathy. We rigorously evaluate these biomarkers through meticulously designed preclinical studies, ensuring reliable outcomes for our clients.
The development of these biomarkers enables us to assist clients in gaining a deeper understanding of the mechanisms underlying cardioembolic stroke, as well as to create more effective diagnostic methods for this condition.
| Type of Biomarkers | Examples |
|---|---|
| Circulating proteins | Markers of myocardial stress: NT-proBNP/BNP, MR-proANP/ANP, cardiac troponin, CK-MB |
| Markers of inflammation: CRP, interleukin-6 (IL-6), interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α) | |
| Markers of coagulation: D-Dimer, fibrin monomer complex, soluble fibrin, fibrin degradation products (FDPs), soluble thrombomodulin | |
| Markers of endothelial dysfunction: sRAGE | |
| Genomic markers | miR-208a, miR-499, and miR-133a |
| Metabolites | The tricarboxylic acid metabolites succinate, α-ketoglutarate, malate, etc. |
Types of Drugs We Can Develop for Cardioembolic Stroke
Ace Therapeutics provides reliable animal models of cardioembolic stroke to help our clients develop effective therapeutic strategies to prevent or treat cardioembolic stroke. We have industry-leading capabilities in assessing the electrophysiological status of the heart (ambulatory electrocardiographic monitoring) as well as its structural and functional status (transthoracic echocardiography) in experimental cardioembolic stroke models.
Accelerate your preclinical drug discovery and development process with the expertise of Ace Therapeutics in cardioembolic stroke. With our profound understanding of cardiac electrical activity and advanced brain imaging techniques, we offer the insights you need to make informed decisions. If you are interested in our services, please contact us for more information.
- Kamel, H., & Healey, J. S. (2017). Cardioembolic stroke. Circulation research, 120(3), 514-526.
- Kato, Y., et al. (2024). Cardioembolic Stroke: Past Advancements, Current Challenges, and Future Directions. International Journal of Molecular Sciences, 25(11), 5777.
